The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
Open accessAbstract
Purpose: This study assessed biomarkers for cetuximab efficacy in tissue samples collected during a phase I dose-escalation study exploring every second week administration of cetuximab as first-line therapy in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Sixty-two patients received cetuximab monotherapy for 6 weeks, followed by cetuximab plus infusional fluorouracil, leucovorin, and irinotecan until disease progression. Patients in the control arm received cetuximab as a 400 mg/m 2 initial dose then 250 mg/m 2 per week; patients in the dose-escalation arms received 400 to 700 mg/m 2 every second week. Tumor and skin biopsies were taken for immunohistochemical and microarray expression analyses (tumor only) at baseline and week 4. Plasma was collected for proteomic analysis at baseline and week 4. KRAS tumor mutation status was assessed. Results: In subsets of paired skin samples from 35 patients, cetuximab treatment was associated with substantial downregulation of phospho(p)-EGFR, p-MAPK and proliferation and substantial upregulation of p27 Kip1 and p-STAT3 levels. No marked difference in these effects was noted for different schedules of administration and dose levels. In the cetuximab monotherapy phase, responses were seen only in patients whose tumors were wild-type for KRAS (eight of 29 v zero of 19 for KRAS mutant tumors; P = .015). Progression-free survival was longer for patients with KRAS wild-type compared with KRAS mutant tumors (log-rank P = .048). Genomics/proteomics analyses (42 and 45 patients, respectively) identified candidate biomarkers associated with response. Conclusion: Biomarker analysis supported the functional equivalence of weekly and every second week administration of cetuximab and provided further confirmation that patients with KRAS wild-type mCRC were those most likely to benefit from cetuximab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while high mRNA levels of either amphiregulin or epiregulin may predict a better response [21, 116-119]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [118]
In the citing paper
“high levels of TGF-α as well as HB-EGF could confer lack of sensitivity [107, 118].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Bonnefoi, H. R., Potti, A., Delorenzi, M., Mauriac, L., Campone, M., Tubiana-Hulin, M., Petit, T., Rouanet, P., Jassem, J., Blot, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70345-5 · Cited by 212
RetractedHsu, D. S., Balakumaran, B. S., Acharya, C. R., Vlahovic, V., Walters, K. S., Garman, K. S., Anders, C. K., Riedel, R. F., Lancaster, J. M., Harpole, D. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0593 · Cited by 106
RetractedBioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,082
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z. J., Irizarry, R. A., Gentleman, R. C., Martínez-Murillo, F., & Spencer, F. A. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,717
Bokemeyer, C., Bondarenko, I., Makhson, A. M., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,646
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–110 of 110
Targeted Therapy in Solid Tumors: Colorectal Cancer
Abdelrahim, M., Kopetz, S., & Menter, D. G. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch20
Spindler, K. G., & Jakobsen, A. K. M. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.98
Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer
Weickhardt, A. J. (2011) · Minerva Access (University of Melbourne)
Clinical results with EGFR inhibitors in colorectal cancer
Martinelli, E., Troiani, T., Morgillo, F., & Ciardiello, F. (2012) · doi:10.2217/ebo.11.378
Self-citationBiomarkers in Metastatic Colorectal Cancer
Diakos, C. I., Charles, K. A., Chua, W. M., Howell, V. M., & Clarke, S. J. (2014) · Springer eBooks · doi:10.1007/978-94-007-7744-6_1-1
Recent Development of Monoclonal Antibodies Targeting Tyrosine Kinase in ROS-Mediated Cancer
Dalal, Y. M., & Kumar, M. S. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_31-1
Recent Development of Monoclonal Antibodies Targeting Tyrosine Kinase in ROS-Mediated Cancer
Dalal, Y. M., & Kumar, M. S. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_31
Zhao, B., Oxnard, G. R., Moskowitz, C. S., Kris, M. G., Pao, W. J., Guo, P., Rusch, V. M., Ladanyi, M., Rizvi, N. A., & Schwartz, L. H. (2023) · doi:10.1158/1078-0432.c.6518304
Analytical Methods in Pharmacoproteomics: A Systematic Review
Okai, C. A., Danquah, B. D., Lartey, M., Oppong, M. B., Amponsah, S. K., Adutwum, L. A., & Opuni, K. F. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-64021-6_4
Metadata
- Authors
- Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., Ramos, F. J., Roselló, S., Celik, I., Stroh, C., Baselga, J., & Ciardiello, F.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- From the Medical Oncology Service, Pathology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona; Department of Hematology and Medical Oncology, Hospital Clinic Universitario, University of Valencia; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain; Division of Medical Oncology, Department of Experimental and Clinical Medicine “F. Magrassi and A. Lanzara,” Second University of Naples, Naples, Italy; and Merck KGaA,...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-01
- Volume
- 28
- Issue
- 7
- Pages
- 1181-1189
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163799638
- Cited by
- 110
- References
- 37
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 8 · 2015: 12 · 2014: 16 · 2013: 15 · 2012: 9
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- cetuximab, metastatic colorectal cancer, pharmacogenomics, pharmacoproteomics, predictive biomarkers, KRAS mutation status, EGFR signaling, MAPK signaling, STAT3, p27, dose escalation, treatment schedule, progression-free survival
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Immunohistochemistry, Mutation, Neoplasm Metastasis, Neoplasm Proteins, Pharmacogenetics, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ras Proteins, Oligonucleotide Array Sequence Analysis, Proteomics, Intracellular Signaling Peptides and Proteins, Cyclin-Dependent Kinase Inhibitor p27, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
